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Abstract: Nuclear receptors (NRs) are important pharmaceutical targets because they  
are key regulators of many metabolic and inflammatory diseases, including diabetes, 
dyslipidemia, cirrhosis, and fibrosis. As ligands play a pivotal role in modulating nuclear 
receptor activity, the discovery of novel ligands for nuclear receptors represents an 
interesting and promising therapeutic approach. The search for novel NR agonists and 
antagonists with enhanced selectivities prompted the exploration of the extraordinary 
chemical diversity associated with natural products. Recent studies involving nuclear 
receptors have disclosed a number of natural products as nuclear receptor ligands, serving to 
re-emphasize the translational possibilities of natural products in drug discovery. In this 
review, the natural ligands of nuclear receptors will be described with an emphasis on their 
mechanisms of action and their therapeutic potentials, as well as on strategies to determine 
potential marine natural products as nuclear receptor modulators. 
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1. Introduction 
Natural products, including compounds from plants, microbes, and marine species, have become 
major resources for bioactive agents and play a key role in the discovery of lead compounds for new 
drug research. The high hit rates in lead drug screening and large-scale structural diversity make marine 
natural products ideal candidates for drug discovery. However, these natural products are often in 
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limited supply, and total synthesis remains difficult. Thus, the bottleneck is a shortage of raw material, 
which has made it very challenging for drug development from marine natural products. Driven by new 
developments in analytical technology, spectroscopy, and high-throughput screening, recent years have 
witnessed a renaissance in marine-based drug discovery since the first marine drug (Ziconotide) came 
out [1,2]. In addition to Ziconotide for the treatment of pain, Trabectedin is another successful marine 
drug for anticancer therapies [3,4]. 
One key approach in drug discovery is to identify a drug target associated with a particular disease 
and to screen for lead compounds that are able to appropriately regulate this target protein. A drug target 
is a functional region of a protein for which a significant fraction of family members have been 
successfully targeted by drugs. The most important feature of drug targets is that they are able to  
respond to small molecules including intracellular metabolites and xenobiotics, such as certain drugs. 
Rhodopsin-like GPCRs, certain ion-channel domains, and nuclear receptors (NRs) are the most 
successful molecular targets in the history of drug discovery [5]. Nuclear receptors, consisting of  
48 members in humans, are important transcriptional factors that play fundamental roles in a broad range 
of biological processes, from development and metabolism to reproductive health [6]. Direct ligand 
binding induces a conformational change in the receptor, allowing it to recruit cofactors in regulating 
transcription [7,8]. The ligands for nuclear receptors include metabolites, vitamins, and hormones, as 
well as xenobiotics. Many nuclear receptors already have one or more ligands currently used as 
medicines, and nuclear receptors represent well-validated drug targets for several human diseases, 
including metabolic syndrome and hormone-dependent cancers (Table 1). 
Two important concerns for drug development are efficacy and clinical safety, which are often 
associated with cross-activity of the compounds with undesired targets. Therefore, all lead compounds 
or drug candidates need to be assessed for toxicity to and selectivity for related targets. A major goal in 
nuclear receptor-targeting drug development has been to obtain ligands that exhibit regulatory activity in 
a receptor-selective manner with reduced adverse side effects. In this review, strategies to determine 
potential marine natural products as nuclear receptor modulators, the interaction between marine natural 
products and nuclear receptors, and potential marine natural products for drug development will be 
discussed and explored. 
Table 1. Disease relevance and drug development of human nuclear receptors. 
NR Related Diseases Drug Development 
CAR 
cholestatic liver disease [9] 
type 2 diabetes [10] 
hematopoietic malignancies [11] 
Phenobarbital [12] 
ER(α, β) 
breast cancer [13] 
ovarian cancer, colon cancer [14] 






biliary cirrhosis,  
non-alcoholic fatty liver disease [9] 
Fexaramine GW4064 [20] 
INT-747 [21] 
GR 
allergic, inflammatory,  
haematological disorders [22] 
Dexamethasone [23] 
RU486 [24] 
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Table 1. Cont. 
HNF4α maturity onset diabetes of the young [25] MEDICA 16 [26] 
LXR(α, β) 
non-alcoholic fatty liver disease [27] 
Alzheimer’s disease [28] 













endothelial detoxification [40] 
liver injury [41] 








thyroid hormone resistance syndrome [47] 








cardiovascular disease [54] 
chronic kidney disease [55,56] 
vascular Disease [57] 
 
PR 




androgen insensitivity syndrome [61] 
prostate cancer [62] 
osteoporosis [63] 
 
RAR(α, β, γ) 
acute promyelocytic leukemia [64] 
kidney disease [65] 
Alzheimer’s Disease [66] 
skin diseases [67] 
cancer [44] 
 
2. Nuclear Receptors: Structure and Function 
Nuclear receptors can be divided into three groups: hormone receptors, adopted orphan receptors, and 
orphan receptors. They share high sequence identity and conserved domains. A typical nuclear receptor 
usually contains four functional regions: The A/B region (N-terminal activation function-1 domain, 
AF-1), the C region (DNA-binding domain, DBD), the D region (hinge region), and the E/F region 
(ligand-binding domain, LBD) (Figure 1A,B) [8]. Among these regions, the DBD and LBD are the most 
conserved. The LBD contains dimerization motifs and an activation function-2 (AF-2), located at the 
C-terminus of the receptor, in which conformation is highly dependent on ligand binding  
(Figure 1C). The LBD interacts with ligands and mediates transcriptional activation in a ligand-dependent 
fashion. Specifically, the binding of ligands to the LBD determines the recruitment of transcriptional 
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coregulators that trigger the induction or repression of target genes (Figure 1D). As ligand binding and 
ligand-mediated cofactor recruitment are crucial for functions mediated by nuclear receptors, the LBD 
plays a critical role in nuclear receptor signaling. Thus, the LBD has been the focus of structural study, 
which has revealed important clues to the binding of ligands and cofactors [68–71]. 
Figure 1. Structural and functional organization of nuclear receptors. (A) Schematic 
diagram for a common domain structure of NR. N-terminal A/B domain includes activation 
function 1 (AF-1), which mediates ligand-independent transcriptional activation. DNA 
binding domain (DBD) dictates specific response element recognition. Hinge region (Hinge) 
links DBD and LBD. C-terminal E/F domain encompasses the ligand-binding domain, 
which mediates ligand-dependent coactivator interactions; (B) Multi-domain structure of the 
HNF4α/DNA complex in cartoon representation. The crystal structure of HNF4α homodimer 
(PDB 4IQR) includes DBD (pink), Hinge (green), LBD (orange) in complex with response 
DNA sequence (left) and ligand (green dots); (C) Enlarged view of HNF4α LBD monomer, 
which clearly shows the three layer sandwich structure; (D) Metabolic regulation of NR. 
Ligand-activated NR complex recruits coactivator proteins that increase transcriptional 
activity of the gene. NRs bind DNA as monomers, homodimers or heterodimers. 
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Figure 2. Structural basis of nuclear receptor ligand binding and cofactor recruitment. The 
structures shown here are the LBD of RXR (green image in the diagram). (A) Apo-RXR  
(no ligand bound, PDB 1LBD) [72]; (B) RXR complexed with agonist BMS649  
(PDB 2ZY0) [73]; (C) RXR complexed with corepressor SMRT (silencing mediator for 
retinoid or thyroid-hormone receptors) (PDB 3R29) [74]. The agonist, coactivator, and 
corepressor are depicted as orange space filling spheres, a red image, and a yellow image, 
respectively. When an agonist is bound to a NR, the C-terminal α helix of the LBD (AF-2, 
blue) changes its position so that a coactivator protein (red) can bind to the surface of the 
LBD (B). Antagonist occupies the same ligand-binding cavity of the NR (antagonist not 
shown). However, antagonist ligands in addition have a side chain extension, which 
sterically pushes AF-2 to move towards outside, and corepressor (yellow) occupies roughly 
the same position in space as coactivators bind. Hence, coactivator binding to the LBD  
is blocked. 
 
All nuclear receptors exhibit similar structural features (Figure 1B). Nuclear receptor LBD structures 
contain 11–13 α-helices that are arranged into a three-layer antiparallel α-helical sandwich [75,76]. The 
three long helices (H3, 7, and 10) form the two outer layers, and the middle layer of helices (H5, 6, 8, and 9) 
is present only in the top half of the domain, thereby creating a cavity for ligand binding, the so-called 
ligand-binding pocket (Figure 1C). The AF-2 also forms a helix that can adopt multiple conformations 
depending on different bound ligands (Figure 2). The first step of nuclear receptor activation is initiated 
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by ligand binding, which induces a conformational change in the receptor; thus, the ligand-binding 
pocket is an important structural feature of nuclear receptors. Upon the binding of an agonist, nuclear 
receptors use a charge clamp pocket, in part composed of the C-terminal AF-2 helix, to form a 
hydrophobic groove for binding of the LXXLL motif of coactivators, such as SRCs (steroid receptor 
coactivators) and GRIP1 (glucocorticoid receptor interacting protein 1), leading to the modulation and 
promotion of gene transcription (Figure 1D). Antagonists block the effect of agonist through 
competitive binding to the same binding site in the nuclear receptor. Therefore, the antagonist-bound 
receptor is in an inactive state and preferentially binds corepressor proteins, leading to the repression of 
gene transcription [77,78]. The corepressors bind to LBDs via a conserved LXXXIXXXL/I motif, which 
is longer than LXXLL coactivator motif and adopts a three-turn α helix. The binding of corepressor 
motif induces major conformation change of AF-2 helix to accomadate the larger corepressor helix. The 
conformational flexibility of AF-2 helix allows the NR to sense the presence of the bound ligand, either 
an agonist or an antagonist, and to recruit the coactivator or corepressors that ultimately determine the 
transcriptional activation or repression of NRs (Figure 2) [8]. 
There is a pressing need to develop detailed structure–function relationships (SAR) of nuclear 
receptor and ligand interaction to facilitate the discovery of potent ligands. Structural comparison and 
analysis show that several features of the ligand-binding pocket have contributed to the ligand binding 
affinity and specificity. The ligand-binding pocket is the least conserved region on LBD, in which size 
and shape varies greatly from receptor subtype to subtype, to further accommodate specific ligands. The 
small pocket seen in the ERRα (estrogen-related receptor α) suggests that only ligands with four to five 
carbon atoms or less can fit [79]. In contrast, the large pocket in PXR (pregnane X receptor) allows the 
binding of antibiotic rifampicin, one of the largest structural ligands for nuclear receptors [80]. The 
overall hydrophobic nature of the ligand-binding pocket allows the NRs to interact with many lipid 
soluble ligands [81,82]. Given the plastic nature of the ligand-binding pockets, NRs respond differently 
to distinct ligands and readily exchange their ligands in different environments. From the drug discovery 
point of view, NRs may possess even greater potential as the flexible ligand-binding pocket allowing 
them to interact with a wider array of pharmacophores. As such, the ligand-binding pockets of nuclear 
receptors are promising sites for drug discovery research. 
NR dimerization is critical in many regulatory processes, as NRs can bind to their  
cognate sequence-specific promoter elements on target genes either as monomers [83–86],  
homodimers [72,87–93], or heterodimers with RXRs (retinoid X receptor α, β, and γ) [75,94–100] 
(Figure 1D). Cooperative DNA binding and distinct recognition sites of homodimer and heterodimer 
make dimerization a general mechanism to increase binding site affinity, specificity, and diversity [101]. 
NR LBD stabilizes the dimers, while NR DBD contributes to response element selection by dictating 
the response element repertoire for monomer, homodimer, or heterodimer receptors. The steroid 
receptors appear to function as homodimers, such as ER (estrogen receptor) [88], PR (progesterone 
receptor) [102], AR (androgens receptor) [103], GR (glucocorticoids receptor) [93], and MR 
(mineralocorticoid receptor) [71]. HNF4α (Hepatocyte nuclear factor 4 alpha) is rather unique in that it 
binds DNA exclusively as a homodimer and, yet, behaves as the subtype nuclear receptors that 
localized primarily in the nucleus and usually activated as heterodimer with RXR [92]. One third of 
known NRs act as heterodimers with RXR, including RARs (retinoic acid receptors) [94,95], VDR 
(vitamin D receptors) [104,105], TR (thyroid hormone receptors) [96], LXR (liver X receptor) [97], 
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CAR (constitutive androstane receptor) [98,99], PPARs (peroxisome proliferator activated  
receptors) [75,100], PXR, and FXR (farnesoid X receptor). Further, RXR self-associates into a 
homodimer or a homotetramer in the active or auto-repressed state [106]. It is suggested that RXR 
exists predominately in inactive homotetramer in the absence of ligand in vivo and dissociates upon 
ligand binding to form homodimer or heterodimers with other NRs [107]. Crystal structures of 
homodimers and heterodimers of NRs have revealed the structural organization of NR dimers. The NR 
dimerizations are mainly mediated by the dimerization surface located on the LBDs, which are 
topologically conserved. The dimeric arrangements are closely related, with residues from helices H7, 
H9, and H10, and loops L8–9 and L9–10 of each protomer, forming an interface comprising a network 
of complementary hydrophobic and charged residues [94]. NGFI-B (Nerve Growth factor IB) [84], 
RevErb [85], ROR (RAR-related orphan receptor) [83], SF-1 (steroidogenic factor 1) [86], and several 
other orphan NRs have been shown to bind DNA as monomers. Interestingly, some NRs have been 
reported to function in multiple patterns. For example, TR can bind to DNA as monomers, 
homodimers, or heterodimers. A single surface mutation, D355R, was shown to be crucial for 
converting the modestly stable monomeric TR LBD into a stable dimer [108]. LXR have been reported 
both as homodimers and heterodimers, and the comparison of these two different dimer patterns 
explains differences in dimer affinity and leads us to propose a model for allosteric activation in LXR 
dimers, in which an unactivated RXR partner provides an inhibitory tail wrap to the cofactor binding 
pocket of LXR [109]. When activated, ER translocates into the nucleus, binding to DNA either as a αα 
homodimer or as a αβ heterodimer [110,111]. 
3. Nuclear Receptors as Drug Targets in Related Disease Signaling 
Extensive studies have revealed that nuclear receptors are involved in many metabolic and 
inflammatory diseases, such as diabetes, dyslipidemia, cirrhosis, and fibrosis [112–117]. As ligands play 
a pivotal role in modulating nuclear receptor activity, agonists or antagonists of nuclear receptors have 
been suggested for pharmaceutical development. The examples of disease relevance of NRs and drug 
development are listed in Table 1. As most marine natural ligands have been reported to target PPARs, 
FXR, PXR, and RARs, the following discussion focuses on the drug discovery targeting these 
well-described NRs as well as their therapeutic uses. 
3.1. Peroxisome Proliferator-Activated Receptor (PPAR) 
Peroxisome proliferator-activated receptors (PPARs, isoforms α, β/δ, and γ) are ligand-activated 
nuclear receptors that play essential roles in lipid homeostasis [34], adipocyte differentiation [118],  
and insulin responses [119]. A large ligand-binding pocket is a distinguishing feature of PPARs,  
which allows them to bind a variety of chemical ligands including fatty acids, fibrates, and the 
thiazolidinedione class of antidiabetic drugs with diverse shapes, sizes, and compositions. The binding 
of ligands causes a conformational change in PPARs and the recruitment of coregulators, such as 
PGC1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), which results in the 
transcriptional regulation of downstream target genes [120–123]. These genes in turn regulate many 
metabolic pathways involved in glucose homeostasis and insulin sensitivity. PPARα is expressed in  
the liver, heart, muscle, and kidneys, and it regulates fatty acid metabolism and transport. PPARγ is 
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expressed in adipose, muscle, and macrophage and is critical for adipogenesis and lipid storage. PPARδ 
is broadly expressed in the body and is involved in fat oxidation, energy expenditure, and lipid storage. 
These biological roles have made PPARs important targets in the treatment of metabolic syndrome  
and diabetes. 
The most extensively studied ligands for PPARs are thiazolidinediones (TZDs), a class of drugs used 
to increase insulin sensitivity. TZDs can decrease insulin resistance, modify adipocyte differentiation, 
and induce lipoprotein lipase (LPL) by regulating the expression of PPARγ target genes [124–127]. 
However, TZDs are clinically limited due to severe adverse effects, such as fluid retention, weight gain, 
liver toxicity, and cardiovascular disease [38,128,129]. Therefore, it is imperative to develop improved 
PPARs ligands that retain the benefits in improving insulin resistance but that have reduced side effects. 
Current approaches include multi-target strategies (ligands targeting more than one PPAR isoform) and 
selectivity strategies (selective PPARγ modulators (SPPARMs)). Some SPPARMs with partial or no 
agonism in transcriptional activity have shown similar glucose-lowering effects to rosiglitazone but with 
reduced side effects [69,130–132]. Recently, we reported two novel ligands for PPARs (RU486 and 
ionomycin) as partial agonists for PPARγ [69,133], which may provide promising therapeutic agents 
targeting PPARs. 
3.2. Farnesoid X Receptor (FXR) 
Farnesoid X receptor (FXR), also known as bile acid receptor, is important in maintaining bile acid 
and cholesterol homeostasis. FXR regulates the expression of transporters and biosynthetic enzymes, 
such as cholesterol 7α-hydroxylase (CYP7A1), which is crucial for the physiological maintenance of 
bile acid homeostasis [134–136]. FXR is highly expressed in the liver, intestine, kidneys, and adrenal 
gland [137–139] and is activated by chenodeoxycholic acid (CDCA) and other bile acids [140,141]. 
Following ligand binding, the transcriptional function of FXR is mediated through the recruitment of 
coactivators such as SRC1 or through the release of specific corepressors such as NCoR1 (nuclear 
receptor corepressor 1) and SMRT [142–144]. FXR regulates lipid metabolism, possibly by interacting 
with PPARα and PPARγ, as well as repressing sterol regulatory element-binding protein-1c 
(SREBP-1c) [145–147]. Activation of FXR by an agonist or hepatic overexpression of FXR lowered 
blood glucose levels in both diabetic db/db and high-fat diet-fed wild-type mice, and FXR-null mice 
exhibited glucose intolerance and insulin insensitivity [148]. 
Given the important roles of FXR in physiological and pathological processes, FXR ligands have 
become promising therapeutic agents for different diseases. Synthetic agonists of FXR (including 
GW4064, INT-747, and fexaramine) have been developed to treat primary biliary cirrhosis and 
non-alcoholic fatty liver disease [149]. However, synthetic FXR ligands have limitations owing to side 
effects and uncertain bioavailability. The application of known natural FXR ligands, such as bile acid 
CDCA, is also limited by their poor selectivity and low affinity [144]. 
3.3. Retinoic Acid Receptor (RAR) 
Retinoic acid receptors (RARs) exist as three subtype isoforms (α, β, and γ) that collectively 
contribute to a response to both natural and synthetic ligands [150,151]. RARα is associated with 
differentiation therapy for human acute promyelocytic leukemia (APL) [44,152]. RARβ plays a crucial 
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role in limiting the growth of different tumor cell types and is thus a promising target for the treatment of 
breast and other cancers [153]. RARγ is primarily expressed in the skin and is involved in skin diseases, 
such as psoriasis and acne [67]. 
RARs activate transcription in a ligand-dependent manner by binding to DNA as heterodimers with 
RXR. Ligand activation of RAR/RXR heterodimers drives physical interactions with co-regulatory 
proteins (corepressors and coactivators) and binding to retinoic acid response elements (RAREs) present 
in the promoter or enhancer regions of target genes. RAR ligand retinoids, which include vitamin A and 
its derivatives, have demonstrated some success as therapeutic agents for a wide range of  
diseases [150,151,154–158]. Retinoids exert their therapeutic effect by activating retinoid receptors, 
including RARs (α, β, and γ) and RXRs (α, β, and γ) [159–161]. For instance, the use of all-trans retinoic 
acid (ATRA), a retinoid panspecific for all RARs, has been very successful in the treatment of APL by 
inducing differentiation of leukemic cells. 
Due to their teratogenic properties, retinoids can result in a number of undesired side effects, such as 
increased serum triglycerides and bone toxicity, presumably due to their panspecific activation of all 
RAR isoforms. Further, the occurrence of RA resistance in a variety of cancer cells is also one  
of the major concerns with retinoid treatments, which hampers RA-based chemotherapy [33]. 
Consequently, there is an urgent need to develop ligands against RARs distinct from retinoids, which 
may yield more efficacious RAR-targeted drugs with less adverse effects. 
3.4. Pregnane X Receptor (PXR) 
By sensing the presence of foreign toxic substances, PXR can up-regulate the expression of proteins 
involved in the detoxification and clearance of these substances from the body [162]. In addition to 
detoxification and metabolism of xenobiotics, PXR is also involved in various physiological and 
pathophysiological processes, such as lipid metabolism [163], glucose homeostasis, and inflammatory 
response [164]. Recent studies suggest that PXR may be a useful target for pharmacological  
therapies in various conditions, including liver disease [165], and inflammatory bowel diseases (IBD), 
encompassing Crohn’s disease (CD) and ulcerative colitis (UC) [164,166]. PXR is activated by a large 
number of endogenous and exogenous chemicals including steroids, antibiotics, antimycotics, bile acids, 
and many other herbal compounds [162]. Following ligand binding, PXR forms a heterodimer with 
RXR and binds to specific PXR response elements (PXREs), located in the N-terminal flanking regions 
of PXR target genes, resulting in their transcriptional activation [167]. Primary targets of PXR activation 
are P450 enzymes (CYP3A, CYP2C, and CYP2B), important phase I oxidative enzymes that are 
responsible for the metabolism of many drugs [167,168]. In addition, PXR up-regulates the expression 
of phase II conjugating enzymes that improve solubility of phase I metabolites (glutathione 
S-transferases [169], sulfotransferases, and UDP-glucoronosyltransferases [170,171]) and phase III 
transport uptake and efflux proteins, such as OATP2 [172] and MDR1 [173,174]. 
PXR LBD shows a typical NRs organization, but its ligand-binding pocket is substantially larger than 
those of many other NRs [175,176]. Therefore, PXR is able to bind both small and large ligands. The 
number of chemicals that are reported to activate PXR has grown rapidly, including many drugs 
currently in use, such as statins, the antibiotic rifampicin, antihypertensive drugs nifedipine and 
spironolactone, anticancer compounds, HIV protease inhibitors, calcium channel modulators, diverse 
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environmental toxicants, such as plasticizers and pesticides [177]. Rifampicin, a semisynthetic PXR 
agonist, is currently used in the treatment of cholestatic liver disease and its exact mechanism of action is 
still under investigation. Notably, most PXR ligands reported show agonism properties, whereas to date 
only few PXR antagonists have been identified [178]. 
4. Strategies for the Discovery of Novel Ligands for Nuclear Receptors 
The discovery of novel ligands for nuclear receptors represents an interesting and promising 
therapeutic approach to various diseases. Both indirect and direct methodologies have been developed to 
identify compounds that bind to nuclear receptors in vitro, generally involving the LBDs. Direct 
approaches are the use of high-throughput screening (HTS) assays to identify compounds capable of 
regulating nuclear receptors; these assays have become increasingly popular because they can rapidly 
and accurately distinguish compounds among large chemical libraries [179]. Improved methods for  
the synthesis of chemical libraries have created a need for increased sensitivity and throughput in 
screening [180,181]. In the field of HTS, there are often various biochemical assays and cell-based 
assays available for efficiently measuring a particular nuclear receptor-ligand interaction; such choices 
are fluorescence polarization (FP), AlphaScreen assays, and transactivation reporter gene assays. 
4.1. Fluorescence Polarization (FP) and Fluorescence Resonance Energy Transfer (FRET) 
Fluorescence polarization (FP) is one of the standard ligand-binding assays, and it is commonly 
deployed in a high-throughput format to measure the rotational speed of a fluorophore during its 
fluorescence lifetime, defined as the duration of time post-excitation by plane-polarized light but prior to 
light emission [182]. In an FP assay, compounds are screened for their ability to compete with a labeled, 
validated LBD-binding ligand. Either an agonist or antagonist can be detected in this type of competitive 
binding assay [183]. A small coactivator peptide alone, containing an LXXLL motif and a fluorophore 
label, rotates quickly, and exhibits low polarization. Ligand binding of nuclear receptors induces the 
formation of a ligand-nuclear receptor-coactivator complex, which is larger and rotates more slowly, 
resulting in the emission of more highly polarized light. Therefore, ligand binding can be quantitatively 
monitored based on the difference in polarization. 
The FRET assay was developed from the FP assay, in which the fluorescent signal intensity depends 
upon the interaction between a fluorescently labeled LBD and coactivator proteins. A fluorescent signal 
is obtained when the LBD is in close proximity to the coactivator proteins through its interaction with a 
putative agonist. In a time-resolved FRET (TR-FRET) assay, lanthanide chelates are used as the donor 
fluorophore and may be used to label either the protein directly or an antibody to a common protein tag. 
A receptor ligand is labeled with fluorescein or some other suitable acceptor fluorophore. Potential 
ligands that compete for LBD binding will result in an associated decrease in the TR-FRET signal. 
TR-FRET assays can greatly reduce data variability because they are able to measure both lanthanide 
and acceptor fluorophore emissions to generate FRET ratios. The FRET ratio is disrupted when a 
competitor ligand binds to the LBD and displaces the bound fluorescein-labeled tracer molecule. 
TR-FRET assays can minimize the nonspecific interference derived from short fluorescent lifetime 
components such as plate plastics, compound autofluorescence, and diffusion-enhanced FRET. 
Moreover, selecting the proper donor and acceptor fluorophores and wavelength filters allows for the 
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monitoring of two simultaneous processes [184]. However, FP assays also have several disadvantages, 
including their high level of background, which translates into a lower signal-to-noise ratio and 
decreased sensitivity, and their inability to distinguish between agonists and antagonists [185]. 
4.2. AlphaScreen (Cofactor Binding Assays) 
AlphaScreen, used mostly in high throughput screening, is a homogenous assay technology similar to 
TR-FRET. AlphaScreen technology was first described in 1994 and is based on the principle of 
luminescent oxygen channeling [186,187]. AlphaScreen is a bead-based, nonradioactive amplified 
luminescent proximity homogeneous assay in which a donor and an acceptor pair of 250-nm-diameter 
reagent-coated polystyrene microbeads are brought into proximity by a molecular interaction of binding 
partners immobilized to these beads [187–189]. The detection system of AlphaScreen can be time-gated, 
as the signal is long lived, thus, eliminating short-lived background signals. The high sensitivity of the 
assay derives from the very low background fluorescence. Furthermore, the detection wavelength is 
shorter than the excitation wavelength, thereby further reducing the potential for fluorescence interference. 
The larger diffusion distance of the singlet oxygen makes the available detection of binding distance 
200 nm, whereas TR-FRET is limited to 9 nm [190]. The most important advantage of AlphaScreen over 
TR-FRET is that the AlphaScreen can distinguish between an agonist and an antagonist by the selective 
usage of coactivator or corepressor peptides. The AlphaScreen system is generally applicable over a wide 
variety of biomolecular targets, which can supplant solid-support binding assays in many applications, such 
as receptor-ligand interactions [191], lipid signaling [192], protein kinase monitoring [193], and other types 
of signaling [194]. 
The unique advantages of AlphaScreen have made it an excellent alternative to TR-FRET for the 
measurement of ligand-induced nuclear receptor-cofactor interactions [195]. A comparison study 
between AlphaScreen and TR-FRET suggested that AlphaScreen would be better because of its 
increased sensitivity, decreased plate reading time, and increased proximity limits [195]. The large 
signal/background ratio and increased sensitivity in the AlphaScreen assay enable a significant 
reduction in the quantities of nuclear receptor protein and biotinyl-cofactor required for screening. For 
the AlphaScreen format, acceptable data can be obtained with five-fold less of these reagents compared 
to the TR-FRET assays. In recent years, more and more NR ligands have been identified by 
AlphaScreen. Our lab also uses AlphaScreen to determine the binding of the various cofactor peptide 
motifs to nuclear receptor LBDs in response to ligands. By using a hexahistidine detection kit from 
PerkinElmer (including the N-terminal biotinyl peptides, His-tag fusion LBD, and compound  
libraries) [68,69,133,196–198], several ligands for various nuclear receptors have been identified, 
including two PPARγ agonists [69,133], a marine natural product as an RAR agonist [196], an existing 
drug as an FXR agonist [68], a dual PPARα and PPARδ agonist [198], and a natural compound as an 
agonist for orphan receptor RORγ [197]. 
4.3. Transactivation Reporter Gene Assays (Transient Transfection Assays) 
Cell-based systems are also widely used for identifying ligands that interact with nuclear receptors. 
Transient and stable transfections are two types of cell-based systems for assessing nuclear receptor 
transactivation. The most common method for evaluating nuclear receptor activation is transient reporter 
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gene assay, through transient transfection of a nuclear receptor together with a cognate response 
element-reporter gene construct. In Gal4-driven reporter assays, the cells are transfected with 
Gal4-LBDs of various nuclear receptors and pG5Luc reporter. In native promoter reporter assays, the 
cells are co-transfected with plasmids encoding full-length nuclear receptors and their cognate luciferase 
reporters (e.g., PPARs and PPRE). Many cell lines are available to serve as recipients of these plasmids, 
including COS7, HuH7, HEK293, HepG2, and other stable tumor cell lines. Many nuclear receptor 
agonists have been identified using transient transactivation systems [199–201]. The advantages of 
reporter gene assays are their ease of use, efficiency, and reproducibility, as well as their ability to 
differentiate mechanisms of action in the nuclear receptor application. Similar to biochemical studies, 
the cell based transactivation assays can also be employed to obtain EC50 values that reflect the potency 
of a compound. This is important as clinical models are based upon EC50 and Emax values to rank a 
compound’s potency [202]. 
The biochemical assays, including FP, FRET, and AlphaScreen assays are straightforward, fast and 
easy to set up, with reasonable cost, enabling the high-throughput screening of a large number of 
chemical libraries. Following biochemical screening, it’s also necessary to perform cell-based assays, 
like a transactivation reporter assay, to validate the functional relevance of the hit compounds. To further 
characterize the underlying molecular mechanisms, various other biological assays and 
structure-activity relationships (SAR) analysis are often critical to gather more insights to optimize the 
hit compounds for future drug discovery. For example, Chromatin Immunoprecipitation (ChIP) is a type 
of immunoprecipitation experimental technique used to investigate coactivators and corepressors 
recruitment modulated by ligands [200,203,204], while real-time PCR allows precise quantification for 
the expression pattern of nuclear receptor target genes regulated by the hit compounds [68,69,200,204]. 
5. Search for Marine Natural Products Targeting Nuclear Receptors 
The value of natural products from marine species has been recognized for over half a century, but it 
is only in recent years there has been a renewed interest in this potential source of new medicines [205]. 
Chemical, structural, and pharmacological characterizations of marine nature products libraries have 
successfully identified many hit compounds that regulate NRs. Recent research has been focusing on 
the development of novel drugs specifically targeting nuclear receptors for treating a variety of diseases, 
such as cancer, diabetes, dyslipidemia, fatty liver disease, drug hepatotoxicity, and cholestasis. 
Searching for novel nuclear receptor ligands (agonists and antagonists) from marine natural products 
with improved selectivity will prompt the exploration of the extraordinary chemical diversity associated 
with natural products. The marine environment has provided a rich source of nuclear receptor ligands, 
and a number of natural products have been shown to display remarkable affinity for nuclear receptors, 
in some cases with unique modes of action (Table 2). These nuclear receptors proven to be targets of 
marine natural products include RAR [196], FXR [206], PPARs [207,208], AR [209], GR [210],  
VDR [211], PR [212], and PXR [213]. In this section, selected examples of the marine natural ligands 
for NRs will be described with an emphasis on their therapeutic potentials. 
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Table 2. List of marine natural molecules targeting nuclear receptors signaling. 
Compounds Origin Target(s) Comments/References Method 
luffariellolide 
Marine sponges 
Luffariella sp. and 
Fascaplysinopsis 
RAR 
agonist of RAR with inhibitory 
effects on cancer cells [196] 
AlphaScreen 











































































potent agonists of PXR and 












PXR potent agonists of PXR [218] transfection assay 
suvanine marine sponge FXR antagonist of FXR [200] transfection assay 
sulfated sterol 
(compound 8) 
marine invertebrates FXR antagonist of FXR [219] transfection assay 
solomonsterols A and B 
marine sponge 
Theonella swinhoei 
PXR agonist of PXR [220] transfection assay 
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Table 2. Cont. 
okadaic acid microalgae 
CiVDR/PXRa, 
hPXR 
activation at nanomolar 
concentration [211] 
transfection assay 
pectenotoxin-2 microalgae CiVDR/PXRa 








highly potent hPPARδ activity 
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activates PPARγ in a MCF-7 
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inhibitor of N-terminus 
transactivation of the  
androgen receptor in prostate 














inhibitory activity against  
FXR with IC(50)’s 14 and 

















PR PR agonist [212] transfection assay 
5.1. Luffariellolide and RARs 
Very few reports on natural ligands of RARs have been reported so far in the literature [196,214,227]. 
Among these natural ligands, 7-hydroxy retinoic acid and luffariellolide were isolated from marine 
organisms. 7-hydroxy retinoic acid is an analog of ATRA isolated from cyanobacteria Microcystis 
aeruginosa and Spirulina sp., and its relative RAR agonistic activity was lower than ATRA [214]. Due 
to its similar structure with RA and RA resistance in a variety of cancer cells, further exploration of 
7-hydroxy retinoic acid in therapy has been limited [228]. Therefore, the search for new RAR ligands 
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other than retinoids with distinct activity profiles and fewer side effects may provide a new rational drug 
design strategy targeting nuclear receptor RARs. Meeting these criteria, luffariellolide may be an ideal 
hit compound for drug design [196]. 
Considering the structural diversity, lower toxicity, and abundance of marine natural products, our 
laboratory set out to search for novel ligands for RARs present in marine products libraries by using  
the AlphaScreen biochemical assay [196]. The marine natural product luffariellolide, a hexane extract 
isolated from sponges of Luffariella sp. and Fascaplysinopsis, was identified as a positive RARα 
activator. Notably, the chemical structure of luffariellolide shows a unique γ-hydroxybutenolide ring 
terminus instead of a carboxylic acid moiety for retinoids, thus, representing a novel approach for an 
RAR ligand design strategy distinct from the retinoid scaffold. In the follow-up study, cell-based 
bioassays were used to attain characteristics of luffariellolide in activating nuclear receptors, and the 
results have shown that luffariellolide was a selective agonist for all three RARs, but not for other NRs, 
including the heterodimer partner RXRα. 
The ability of luffariellolide to promote recruitment of coactivator motifs by RARs was determined 
and the results were consistent with that of the cell reporter assay. Moreover, we were also able to obtain 
the crystal structure of luffariellolide bound to the LBD of RARα, which revealed the molecular basis for 
the binding of luffariellolide by RARs (Figure 3A,B). By structural comparison between the 
luffariellolide-RARα complex and the ATRA-RARα complex, a unique binding mode of luffariellolide 
to RARα was identified. Strikingly, the luffariellolide-RARα structure revealed a covalent interaction 
between the ligand and the receptor, in addition to several hydrophobic and van der Waals interactions. 
Specifically, a covalent bond formed between the Cys
235
 in RARα and the ketone on the unique 
γ-hydroxybutenolide group of luffariellolide (Figure 3C). The covalent interaction has been further 
confirmed by mass spectrometry (MS) and by mutagenesis studies of RARα LBD. Incubation of RARα 
LBD with luffariellolide yielded a mass addition corresponding to the molecular mass of the 
luffariellolide ligand. In the mutagenesis study, both the C235A and C235L mutations abolished the 
activation of RARα by luffariellolide, suggesting the critical roles of this covalent modification for the 
receptor-luffariellolide interaction. 
Next, several cell-based experiments were conducted to assess the roles of luffariellolide in 
regulating the physiological functions of RARs. Luffariellolide could reduce cell proliferation and 
induce known RA-inducible genes in various cancer cells (Figure 3D). Of significance is the observation 
that in an RA-resistant HCT-116 cell line, in which retinoids failed to show effect, luffariellolide was 
able to function as an RAR agonist, reducing cell proliferation and switching on target genes. In future 
studies, it will be worth investigating if luffariellolide can act in suitable in vivo disease models with the 
downstream target gene responsible for overcoming RA-resistance using luffariellolide as a probe. 
Taken together, as a novel RAR agonist, marine natural product luffariellolide may provide an 
alternative drug design strategy for non-retinoid compounds with advantages over current RA drugs. 
The unique characteristics of the γ-hydroxybutenolide ring may represent a new pharmacophore that can 
be optimized for selectively targeting RARs. 
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Figure 3. The structure and gene regulation of luffariellolide bound RARα. (A) Intact 
structure of RARα LBD-Luffariellolide complex. Luffariellolide-bound RARα adopts a 
dimer fold. The RARα LBD (green) and coactivator SRC1 (red) motif are depicted in image 
representation, and luffariellolide is shown in yellow ball and stick representation;  
(B) Enlarged view of the ligand-binding pocket of RARα. AF-2, together with Helix 3,  
Helix 5, and Helix 10, form a ligand-binding pocket for luffariellolide; (C) Interaction 
analysis of luffariellolide by Ligplot [229]. Cys
235
 from Helix 3 of RARα LBD forms a 
covalent bond with the ketone group of the γ-hydroxybutenolide ring terminus from 
luffariellolide; (D) Gene regulation by RARα in the presence of luffariellolide. 
Luffariellolide treatment can inhibit the cell proliferation of monocytic leukemia cell line 
THP-1, RA-sensitive colon cancer cell line HCT-115, RA-resistant colon cancer cell line 
HCT-116, promyeloid leukemic cell line HL-60, and breast carcinoma line MCF-7 [196]. 
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5.2. Marine Products Targeting FXR 
Marine sponges Theonella species have been proven to be an extraordinary source of unusual new 
chemical entities, mainly peptides and macrolides, with impressive biological activities [217]. Apart from 
anti-inflammatory peptides [230] and cytotoxic macrolides [231], recent chemical and pharmacological 
analysis of several Theonella extracts has furnished a large family of molecules able to target FXR and 
PXR, including solomonsterols [220,232] and a large number of 4-methylenesteroids [213,216–218]. 
Solomonsterols A and B were identified to stimulate the expression of CYP3A4 and MDR1, two well 
characterized PXR responsive genes, making them potential hit compounds for the treatment of human 
disorders characterized by inflammation and dysregulation of innate immunity [220,232]. Further 
pharmacological studies in animal models of colitis demonstrated that synthetic solomonsterol A 
effectively protects against development of clinical signs and symptoms of colitis and reduces the 
generation of TNFα, a signature cytokine for this disorder [232]. Within the family of 4-methylenesteroids, 
theonellasterol, the major component of the steroidal fraction of Theonella swinhoei, was identified as a 
highly selective FXR antagonist with pharmacological potential in the treatment of cholestasis [204]. 
Theonellasterol directly inhibits FXR transactivation caused by CDCA and reverses the effect of CDCA 
on the expression of canonical FXR target genes. In rodent models of cholestasis, theonellasterol 
attenuates liver injury caused by bile duct ligation. Interestingly, 4-methylenesterols derived from 
marine sponge Theonella swinhoei, was found to have potent PXR agonist activity and FXR antagonist 
activity [213,216–218]. The dual behaviors of these marine natural compounds may lead to combination 
therapies involving lower drug doses and therefore reduced side effects. 
Hepatic FXR activation leads to both beneficial actions and potentially undesirable side effects such 
as the inhibitions of bile acids synthesis and basolateral efflux of bile acids [233]. These findings have 
raised the notion that FXR antagonists might be useful in the treatment of liver disorders caused by 
impairment of bile secretion [204]. However, only few FXR antagonists are known and the main 
contribution is derived from terrestrial and marine natural compounds [228]. Most of the FXR 
antagonists have a steroid skeleton [219,220,232,234,235]. The steroidal FXR antagonists may also 
regulate steroid receptors and are unsuitable for studying FXR physiology. Therefore, the discovery of 
nonsteroidal FXR antagonists is highly desirable. 
Six nonsteroidal FXR antagonists from the Korean marine tunicate Botryllus tuberatus were 
identified, including the isoprenoid tuberatolide A, a pair of diastereomeric meroterpenoids (tuberatolide 
B and 2′-epi-tuberatolide B), and three meroterpenoids (yezoquinolid, (R)-sargachromenol, and 
(S)-sargachromenol) [206]. They show potent inhibition of FXR transactivation without significant 
cytotoxicity. More importantly, these compounds have no effects on steroid receptors in transactivation 
experiments. Structurally, the six compounds all have γ-lactones or carboxylic acids at the C-15 
position, suggesting that the carbonyl group at C-15 may enhance the FXR antagonistic effects and may 
help to unravel the controversial function of FXR in atherosclerosis [206]. 
Sesterterpenes isolated from marine sponges are particularly interesting from their pharmacological 
properties. There is no report of biological activity of scalaranes in regard to metabolic disorders  
until the discovery of five novel scalarane sesterterpenes with FXR inhibitory activities [215]. All five 
sesterterpenes were isolated from marine sponge Spongia sp. and showed inhibitory activities against 
FXR transactivation. Notably, 12,24-diacetoxy-deoxoscalarin showed the most potent inhibitory 
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activity with an IC50 value of 8.1 µM without any significant cytotoxicity [215]. In addition, suvanine, a 
furano sesterterpene sulfate from the marine sponge Coscinoderma mathewsi, was reported as a novel 
antagonist of the mammalian bile acid sensor FXR [200]. 
5.3. Marine Products Targeting PPARs and AR 
As for PPARs, a master regulator of adipocyte differentiation, psammaplin A from the sponge 
Pseudoceratina rhax and herdmanine from the marine ascidian Herdmania momus were both revealed 
to activate PPARγ [223]. In addition, the marine natural products sargaquinoic acid (SQA) and 
sargahydroquinoic acid (SHQA) from Sargassum yezoense were reported as novel PPARα/γ dual 
agonists. SQA and SHQA increased adipocyte differentiation accompanied by increased expression of 
adipogenic marker genes, suggesting that these PPARα/γ dual agonists may reduce insulin resistance 
through regulating adipogenesis [207]. SQA, also named aleglitazar, already entered phase III clinical 
trials for the treatment of type 2 diabetes but failed due to its inacceptable side effects related to bone 
fractures, heart failure, and gastrointestinal bleeding [236]. Gracilioether B and plakilactone C isolated 
from the marine sponge Plakinastrella mamillaris were identified as selective PPARγ ligands in 
transactivation assays. Both agents regulate the expression of PPARγ-dependent genes in the liver and 
inhibit the generation of inflammatory mediators by macrophages. More importantly, these two marine 
natural compounds covalently bind to the PPARγ LBD through a Michael addition reaction involving a 
cysteine residue and the α,β-unsaturated ketone in their side chains, suggesting the possibility to develop 
novel PPARγ modulators as potential agents in the treatment of inflammatory disorders [222]. 
Interestingly, several marine natural products with antagonism activities interact with AR at its 
N-terminal domain, not the LBD, including a group of glycerol ethers (niphatenones) from the sponge 
Niphates digitalis [209] and a group of chlorinated peptides, termed sintokamides, from the sponge 
Dysidea sp. [224]. These two AR antagonists demonstrate the possibility of targeting regions other than 
the traditional LBDs to modulate NR activity, thus, providing an alternative method for NR ligand 
screening to overcome hormone resistance. 
6. Conclusions 
As the pathogenesis of diseases is complicated, the development of safe and effective drugs against 
diseases is full of challenges. Currently, nuclear receptors have been engaged in hit compound discovery 
as important targets involved in disease. In comparison with synthetic compounds, natural products 
possess multiple advantages for their large-scale structures and target diversity both in single target and 
signaling pathway-based drug discovery strategies. In addition, the complex structures of natural 
products lead to great target diversity. Therefore, natural molecules often function as good probe 
candidates for exploring novel targets or pathways involved in diseases. 
The marine environment has long been known to be species-rich. Recent studies have revealed more 
and more marine natural products as nuclear receptor modulators, which highlights the translational 
possibilities of natural products in drug discovery. Many emerging strategies have been developed to 
speed up the drug discovery process, including natural product isolation technologies, compound 
synthesis and optimization methods, and high-throughput screening technologies. It is reasonable to 
expect that interaction between marine natural products and nuclear receptors will continue to provide 
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more hit compounds, as well as a mechanistic understanding for drug discovery targeting nuclear 
receptors, thereby, greatly facilitating the development of therapeutic reagents against human diseases. 
Taken together, the discovery of NR ligands in marine natural products and their derivatives opens  
a promising approach for the design and preparation of new potential leads in the pharmacological 
treatment of NR-mediated human diseases. 
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